Biohaven .(US:BHVN) Prnewswire·2025-09-02 12:45Core Viewpoint - A class action securities lawsuit has been filed against Biohaven Ltd. alleging securities fraud that negatively impacted investors between March 24, 2023, and May 14, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Biohaven Ltd. made false statements regarding the regulatory prospects of its product candidate, troriluzole, and the efficacy of BHV-7000 for bipolar disorder, which were overstated [2]. - The complaint suggests that the revelation of these issues would likely have a significant negative impact on Biohaven's business and financial condition, indicating that the public statements made by the defendants were materially false and misleading [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until September 12, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, emphasizing that there is no cost or obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].